The Prognostic Significance of Atrial Fibrillation and Left Atrium Size in Patients with Aortic Stenosis.

Aim    Aortic stenosis increases left atrial (LA) pressure and may lead to its remodeling. This can cause supraventricular arrhythmia. The aim of this study was to determine if the size of the LA and the presence of atrial fibrillation are related to the prognosis of patients with aortic stenosis.Material and methods    Clinical evaluation and standard transthoracic echocardiographic studies were performed in 397 patients with moderate to severe aortic stenosis.Results    In all patients, LA dimension above the median (≥43 mm) was associated with a significantly higher risk of death [HR 1.79 (CL 1.06-3.03)] and a LA volume above the median of 80 ml was associated with a significantly higher risk of death [HR 2.44 (CI 1.12-5.33)]. The presence of atrial fibrillation was significantly associated with a higher risk of death (p <0.0001). The presence of atrial fibrillation [HR 1.69 (CI 1.02-2.86)], lower left ventricular ejection fraction [HR 1.23 (CI 1.04-1.45)], higher NYHA heart failure class [HR 4.15 (CI 1.40-13.20)] and renal failure [HR 2.10 (CI 1.31-3.56)] were independent risk factors of death in patients in aortic stenosis.Conclusion    The size and volume of the LA and the occurrence of atrial fibrillation are important risk factors for death in patients with aortic stenosis. The presence of renal dysfunction, low left ventricular ejection fraction, high NYHA functional class and atrial fibrillation are independent risk factors of poor prognosis in patients with aortic stenosis.

Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.

Valvular heart disease is associated with an increased thromboembolic risk. Impaired fibrinolysis was reported in severe aortic stenosis (AS). Little is known about fibrinolysis in mitral stenosis (MS). We sought to compare fibrinolysis impairment in AS and MS. We studied 121 individuals scheduled for elective aortic valve (AV) or mitral valve (MV) surgery for AS (n = 76) or MS (n = 45), in order to compare fibrinolysis impairment. Fibrinolytic capacity was assessed by determination of clot lysis time (t50%) and fibrinolysis inhibitors, including plasma plasminogen activator inhibitor-1 (PAI-1) antigen (PAI-1:Ag) and activity, thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity. Prolonged t50% (+ 29%), elevated TAFI activity (+ 12%), TAFI:Ag (+ 21%), and PAI-1:Ag (+ 84%) were observed in patients with MS, compared with those with AS. t50% Correlated with mean and maximal MV gradients (r = 0.43, p < 0.0001 and r = 0.39, p < 0.0001, respectively), but not with AV gradients. Mean and maximal MV gradients correlated with TAFI activity and PAI:Ag. Patients with permanent atrial fibrillation (AF; 35 with MS and 5 with AS) had longer t50% (by 22%, p = 0.0002) and higher PAI-1:Ag (by 74%, p < 0.0001) than the remainder. In the whole group, postoperative drainage volumes correlated inversely with PAI-1:Ag (r = - 0.22, p = 0.02). MS is associated with more pronounced impairment of global fibrinolytic capacity than AS at the stage of surgical intervention, which is in part driven by AF. Our findings suggest that hypofibrinolysis might be implicated in the progression of MS and its thromboembolic complications.

[Prospective assessment of circulatory sufficiency of the patients after 3F equine pericardial stentless bioprosthesis replacement]. / Prospektywna ocena zmiany wydolnosci serca u pacjentów z wszczepiona bezstentowa, biologiczna zastawka aortalna wykonana z osierdzia konskiego.

INTRODUCTION: During years more and more advanced Technologies are used for treatment of severe aortic stenosis. One of them is equine pericardial stentless bioprothesis. AIM OF THE STUDY: the aim of the study was prospective assessment of circulatory sufficiency of the patients after 3F equine pericardial stentless bioprothesis replacement (ATS-Medtronic, Inc, Minneapolis, USA). PATIENTS AND METHODS: Patients qualified to valve replacement were qualified to the study. The procedures were performed in general anesthesia and medial thoracothomy. The New York Heart Association (NYHA) scale was analyzed to estimate clinical results of the procedures. RESULTS: 45 patients (10 women and 35 men) aged 23-78 (mean 54 (+/- SD 12.7) were included into the study. Patients were observed during one-year follow up (FU). At the baseline three pts had NYHA II stage, 35 - III and 7 - IV. There was no pts in NYHA I stage. After 3-6 months FU 34 pts were at NYHA I stage (79%) and 9 at NYHA II. After 11-14 FU 33 pts were at NYHA I (80.4%) and 8 NYHA II (19.5%). There was no pts at NYHA IV during 12 months FU (differences between observational periods statistically significant p < 0.001). CONCLUSIONS: During one-year FU after equine pericardial stentless bioprothesis implantation the improvement of NYHA grade was observed.

[Clinical evaluation of complications after implantation of stentless biological equine pericardial bioprothesis]. / Ocena powiklan po wszczepieniu bezstentowej, biologicznej zastawki aortalnej wykonanej z osierdzia konskiego.

UNLABELLED: Stentless bio-protheses are more and more frequently used in patients with severe aortic stenosis, due to good hemo-dynamic parameters and durability after aortic valve replacement (AVR). Aim of the study was the clinical evaluation of complications after surgical AVR using the 3F equine pericardial stentless bioprothesis (ATS Medtronic, Inc, Minneapolis, USA). PATIENTS AND METHODS: 45 patients (10 women, 35 men), aged from 23 to 78 had implanted the bioprothesis. RESULTS: Two patients died in perioperative period, but the bioprotehsis function was correct. In two patients gastrointestinal (GE) bleeding was observed due to anticoagulation therapy. In remaining 41 patients during one year follow-up no complications were noted. CONCLUSIONS: After implantation 3F bioprotehesis two unrelated deaths and 2 GE bleeding complications were observed. Other 41 patients had no complications during 1 year follow-up.

[Thoracoscopic Ex-Maze III procedure and radiofrequency catheter ablation - a hybrid therapy for permanent atrial fibrillation. A case report]. / Leczenie hybrydowe obejmujace torakoskopowa procedure Ex-Maze III i przezcewnikowa ablacje pradem o czestotliwosci radiowej u chorego z utrwalonym migotaniem przedsionków - opis przypadku.

We desribe a case of a 57-year-old patient with persistent longstanding atrial fibrillation (AF) in whom paracardioscopic Ex-Maze III procedure converted AF to typical counterclockwise atrial flutter. Subsequent catheter RF ablation of cavo-tricuspid isthmus restored sinus rhythm. We propose that the hybrid therapy including thoracoscopic maze procedure and catheter RF ablation of flutter isthmus might be effective in some patients with permanent AF. To the best of our knowledge this approach was never published before. Lelako.

Cardiac metastasis due to pulmonary metastasis from a transitional cell carcinoma.

We report a rare case of symptomatic cardiac metastasis from a transitional cell carcinoma of the renal pelvis diagnosed by echocardiography. A 75-year-old patient with a long history of neoplasm since 1999 and coronary artery disease with CABG in 2003, was admitted to our department. He underwent cardiac surgery using cardiopulmonary bypass with tumor excision. Histologically it was the same type of transitional cell neoplasm which was operated seven years before. We present all medical history, detailed 2D and 3D echocardiography, intraoperative pictures and discuss possible chain of changes from renal pelvis cancer to clinical manifestation of cardiac mass. There is proved a rapid progression of cardiac tumor with clinical manifestation few months after control TEE examination without any evidence of cardiac mass. It is important that this is a very rare case of left heart metastasis from right side of circulatory system through pulmonary stage of cancer progression.

Efficacy of intra-operative radiofrequency ablation in patients with permanent atrial fibrillation undergoing concomitant mitral valve replacement.

BACKGROUND: Permanent atrial fibrillation (AF) is present before operation and persists after surgery in 30-40% of patients undergoing mitral valve surgery. Using the maze procedure, 75-82% of patients can be cured of AF, but the procedure is difficult and long lasting. Percutaneous radiofrequency (RF) ablation has emerged as an effective therapy for AF in recent years. AIM: To assess the efficacy of intra-operative RF ablation of AF in patients undergoing mitral valve surgery. METHODS: 100 adults with permanent AF underwent mitral valve replacement. Patients were divided into two groups: the RF group--50 patients qualified for mitral valve replacement and RF ablation; and the control group--50 patients selected for mitral valve replacement without ablation. Odds ratio and 95% confidence interval were examined to assess the influence of several factors on the outcome (free from AF during one-year follow-up based on symptoms and serial Holter ECG recordings). RESULTS: Baseline clinical, demographic and echocardiographic characteristics were similar in both groups. Electrical cardioversion following surgery was required in 76% of patients from the RF group compared with 94% from the control group (p<0.002). In those who underwent cardioversion, sinus rhythm was restored more frequently in RF than control patients (32 vs. 16%, p<0.002). Sinus rhythm at hospital discharge was present in 56% of RF patients compared with 22% of controls (p=0.0001), and after one-year follow-up in 54 vs. 16% (p<0.001), respectively. The use of amiodarone was significantly lower in RF patients compared with controls (32 vs. 70%, p<0.05). NYHA class III (OR 8.5, CI 1.0-394) or IV (OR 36, CI 1.2-1958) and left atrial diameter >6 cm (OR 9.3, CI 0.5-5230) were identified as predictors of AF. CONCLUSIONS: Intra-operative RF ablation performed in the left atrium in patients with chronic AF undergoing mitral valve replacement significantly improves sinus rhythm restoration rate. Advanced heart failure (NYHA class IV) and left atrial diameter >6 cm are negative prognostic factors for sinus rhythm maintenance.

[Surgical revascularization in patients with acute coronary syndromes: early outcome]. / Chirurgiczna rewaskularyzacja serca u chorych z ostrymi zespolami wiencowymi: wyniki wczesne.

OBJECTIVE: Between January 1 2001 and June 30 2002, 2204 CABG procedures were performed in our institution. 110 patients underwent urgency CABG within six hours of ACS. We analyzed their short-term results. METHODS: 55 patients underwent CABG for UAP, 31 for STEMI and 24 for NSTEMI. In the control group, 55 patients underwent elective revascularization. Preoperative, intraoperative, and postoperative data were analyzed. RESULTS: Hospital mortality was 12.9%, 8.3%, 7.3% and 1.9% for groups with STEMI, NSTEMI, UAP and stable angina, respectively. Independent predictors of early mortality, in order of decreasing importance, were: preoperative extracardiac arteriopathy (p = 0.0002), cardiac arrest befor CABG (p = 0.0003), preoperative shock (p = 0.003), STEMI (p = 0.03) and LVEF < 40% (p = 0.03). CONCLUSIONS: CABG procedures should be a standard part of ACS treatment. Patients with UAP and NSTEMI can be safely operated during the early course of ACS. CABG can be performed with acceptable early-term risk in patients with STEMI and hemodynamic instability.

Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience.

OBJECTIVES: The purpose of the study was to determine the efficacy and safety of left atrial appendage (LAA) closure via a percutaneous LAA ligation approach. BACKGROUND: Embolic stroke is the most devastating consequence of atrial fibrillation. Exclusion of the LAA is believed to decrease the risk of embolic stroke. METHODS: Eighty-nine patients with atrial fibrillation were enrolled to undergo percutaneous ligation of the LAA with the LARIAT device. The catheter-based LARIAT device consists of a snare with a pre-tied suture that is guided epicardially over the LAA. LAA closure was confirmed with transesophageal echocardiography (TEE) and contrast fluoroscopy immediately, then with TEE at 1 day, 30 days, 90 days, and 1 year post-LAA ligation. RESULTS: Eighty-five (96%) of 89 patients underwent successful LAA ligation. Eighty-one of 85 patients had complete closure immediately. Three of 85 patients had a ≤ 2-mm residual LAA leak by TEE color Doppler evaluation. One of 85 patients had a ≤ 3-mm jet by TEE. There were no complications due to the device. There were 3 access-related complications (during pericardial access, n = 2; and transseptal catheterization, n = 1). Adverse events included severe pericarditis post-operatively (n = 2), late pericardial effusion (n = 1), unexplained sudden death (n = 2), and late strokes thought to be non-embolic (n = 2). At 1 month (81 of 85) and 3 months (77 of 81) post-ligation, 95% of the patients had complete LAA closure by TEE. Of the patients undergoing 1-year TEE (n = 65), there was 98% complete LAA closure, including the patients with previous leaks. CONCLUSIONS: LAA closure with the LARIAT device can be performed effectively with acceptably low access complications and periprocedural adverse events in this observational study.

Feasibility of closed-chest ligation of the left atrial appendage in humans.

BACKGROUND: Atrial fibrillation is associated with an increased risk of embolic events. The left atrial appendage (LAA) is believed to be an incubator for thrombus formation. LAA exclusion has been advocated to potentially reduce embolic events arising from the LAA. OBJECTIVE: The aim of the study was to determine the feasibility of a closed-chest surgical suture ligation of the LAA in man. METHODS: Thirteen patients undergoing either mitral valve surgery (n = 2) or electrophysiological study and radiofrequency catheter ablation for atrial fibrillation (n = 11) underwent ligation of the LAA with the LARIAT snare device. In patients having an ablation procedure, pericardial access was obtained prior to the patients undergoing radiofrequency catheter ablation. After transseptal catheterization, endocardial and epicaridal magnet-tipped guide wires were positioned under fluoroscopic guidance to stabilize the LAA. Transesophageal echocardiography (TEE) was used as guidance for positioning a marker balloon at the ostium of the LAA. An over-the-wire approach was used to guide the LARIAT snare device over the LAA to allow closure and suture ligation of the LAA. TEE and contrast fluoroscopy were used to confirm acute closure of the LAA. RESULTS: Both mitral valve replacement (MVR) patients had complete closure of the LAA determined by visual inspection. Ten of 11 patients having ablation underwent a successful closed-chest LAA ligation procedure with TEE and contrast fluoroscopy verification of closure of the LAA. Only one of 11 procedures was terminated owing to the lack of echocardiography guidance of the snare over the marker balloon. One patient with pectus excavatum did have ligation of his LAA; however, a thorascopic procedure was required to remove the snare from the LAA owing to compression of the LARIAT by the concave sternum. There were no other significant complications. CONCLUSIONS: Catheter-based surgical suture ligation of the LAA is feasible in humans. This novel catheter approach may be appropriate for patients with atrial fibrillation who are ineligible for anticoagulation therapy. Further investigation is needed to demonstrate the long-term safety and efficacy of LAA closure.